Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

351
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

371
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

354
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

Clinical lung cancer·2026
Same author

Electroencephalography during acute painful procedures in neonates: a scoping review.

Pain reports·2026
Same author

"We've managed to find our own path of how we do it": exploring parental perceptions of using age-inappropriate formulations at home-a qualitative study.

Frontiers in pediatrics·2026
Same author

Endotracheal surfactant for infants with life-threatening bronchiolitis (BESS): a randomised, blinded, sham-controlled, phase 2 trial.

The Lancet. Respiratory medicine·2026
Same author

Integrating family integrated care into neonatal practice: nursing experiences and education program development-A qualitative study.

Frontiers in pediatrics·2026
Same author

Key role of oxidizing species driving water oxidation revealed by time-resolved optical and X-ray spectroscopies.

Nature materials·2026
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Related Experiment Video

Updated: Feb 22, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.8K

Frameworks for Evaluating Medicines in Children.

Mark A Turner1, Steven Hirschfeld2

  • 1Institute of Translational Medicine, University of Liverpool, Liverpool Women's Hospital, Liverpool, United Kingdom.

Clinical Therapeutics
|October 3, 2017
PubMed
Summary
This summary is machine-generated.

Evaluating medicines in children requires tailored research approaches due to developmental differences. Understanding these pediatric drug development needs is crucial for diverse research communities.

Keywords:
children and young peopledrug developmentmedicines availabilitytherapeutics

More Related Videos

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.7K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

574

Related Experiment Videos

Last Updated: Feb 22, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.8K
Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

18.7K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

574

Area of Science:

  • Pediatric pharmacology and drug development research.
  • Regulatory science and policy in medicine evaluation.
  • Clinical trial design and ethical considerations in pediatrics.

Background:

  • Children and young people exhibit unique physiological and developmental characteristics necessitating distinct drug research methodologies.
  • Current practices in pediatric medicine evaluation often face misunderstandings among various stakeholder groups.

Purpose of the Study:

  • To provide a comprehensive overview of current strategies for evaluating medications in pediatric populations.
  • To highlight and clarify frequently misunderstood aspects of pediatric drug development for all involved parties.

Main Methods:

  • A narrative review synthesizing existing literature.
  • Integration of practical experience from diverse research and clinical settings.

Main Results:

  • Pediatric drug development necessitates specific considerations for sample collection, recruitment, informed consent, and assent.
  • Optimizing pediatric drug research involves early engagement with children, minimizing research burden, and leveraging existing high-quality data, including extrapolation.
  • Regulatory frameworks, academic contributions, and industry collaboration are vital for advancing pediatric pharmacotherapy.

Conclusions:

  • Enhanced comprehension of pediatric-specific issues is essential for researchers and professionals aiming to improve medication therapies for children.
  • Collaboration among regulators, academics, and the pharmaceutical industry can significantly improve pediatric drug development outcomes.